IT giants are betting hundreds of billions of dollars on soaring AI use and the environmental impact promises to be catastrophic.
The deadliest US flu season in decades was expected to immunise CSL’s vaccine business from a growing anti-vaxxer sentiment. That’s not how it has played out.
James Hardie investors have dumped chairwoman Anne Lloyd and two other board members in an unprecedented display of anger,and its CEO may be next.
Investors have called for the WiseTech founder’s departure,but it could wipe billions from its market valuation,warns an analyst.
A further plunge in US vaccination rates since the appointment of vaccine sceptic Robert F. Kennedy Jr has sparked a fresh earnings blow to biotech giant CSL.
The $20 billion group’s disgraceful year will come to a head this week as investors try to wrest back control from an underperforming board seeking a huge pay hike.
Judith Swales has put trust and culture as top company priorities,even as she ducked questions about the board’s controversial backing of a CEO it ultimately sacked.
Billionaire Gina Rinehart will be just one of the beneficiaries of Trump’s multibillion dollar announcement on critical minerals and rare earths with Australia.
With Tabcorp shares soaring,investors were in no mood to deny yet another multimillion-dollar CEO options package for former AFL boss Gillon McLachlan.
Super Retail Group’s humiliating settlement of a legal battle with its former top lawyers,after sacking its CEO,will not prevent a backlash from investors.